🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06455124
Recruiting Phase 2

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

NCT06455124 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Phase 2
Started
2024-05-08
Last updated
2024-06-13

Condition(s) studied

Rectal Cancer

Investigational drug(s) / intervention(s)

RadiationPD-1 antibodyCapecitabineOxaliplatin

Radiation: Shor-course radiotherapy: 25Gy/5Fx

PD-1 antibody: PD-1 antibody (Toripalimab): 240mg d1 q3w

Capecitabine: Capecitabine: 1000mg/m2 d1-14 q3w

Oxaliplatin: Oxaliplatin: 130mg/m2 d1 q3w

Study summary

This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. age 18-75 years old, female and male 2. pathological confirmed adenocarcinoma 3. the distance from anal verge ≤ 7 cm 4. pT1 after local excision of the primary rectal cancer, with at least one of the high-risk features including margin positivity/very close margin (\<1mm) at time of local excision, depth of invasion \>1 mm or SM3 invasion (submucosal invasion to the lower third of the submucosal level), high grade or poorly differentiated, lymphovascular invasion, perineural invasion, tumour budding, or pT2 tumor. 5. refuse radical surgery 6. without pelvic or distance metastases 7. KPS \>=70 8. with good compliance 9. microsatellite repair status is MSS/pMMR 10. without previous anti-cancer therapy or immunotherapy 11. signed the inform consent Exclusion Criteria: 1. pregnancy or breast-feeding women 2. pathological confirmed signet ring cell carcinoma 3. history of other malignancies within 5 years 4. serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc. 5. immunodeficiency disease or long-term using of immunosuppressive agents 6. baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/L, Hb≥90g/L, PLT≥100×10\^9/L, ALT/AST ≤2.5 ULN, Cr≤ 1 ULN 7. DPD deficiency 8. allergic to any component of the therapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fudan University Shanghai Cancer Center Shanghai China Recruiting

More Fudan University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06455124 on ClinicalTrials.gov ↗ ← All trials in China